Compare Stocks: PROK, LKFT, OCUL, and ANIP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$79.02 -0.3%	$81.13	$63.67 ▼ $99.50	$1.80B	0.44	371,843 shs	86,699 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$26.59 -2.3%	$28.81	$26.41 ▼ $37.78	$1.75B	0.25	154,030 shs	31,952 shs
OCUL Ocular Therapeutix	$8.37 +2.4%	$9.15	$6.23 ▼ $16.44	$1.85B	0.93	4.26 million shs	244,537 shs
PROK ProKidney	$1.57 +1.6%	$1.73	$1.45 ▼ $3.55	$472.42M	1.66	1.00 million shs	39,407 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	0.00%	+2.05%	-7.89%	-1.43%	+23.95%
LKFT Lakefront Biotherapeutics American Depositary Shares	0.00%	-2.26%	-10.46%	-2.82%	-16.81%
OCUL Ocular Therapeutix	0.00%	-4.00%	-15.25%	-13.36%	-31.46%
PROK ProKidney	0.00%	+2.67%	-24.14%	-20.21%	-45.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$79.02 -0.3%	$81.13	$63.67 ▼ $99.50	$1.80B	0.44	371,843 shs	86,699 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$26.59 -2.3%	$28.81	$26.41 ▼ $37.78	$1.75B	0.25	154,030 shs	31,952 shs
OCUL Ocular Therapeutix	$8.37 +2.4%	$9.15	$6.23 ▼ $16.44	$1.85B	0.93	4.26 million shs	244,537 shs
PROK ProKidney	$1.57 +1.6%	$1.73	$1.45 ▼ $3.55	$472.42M	1.66	1.00 million shs	39,407 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	0.00%	+2.05%	-7.89%	-1.43%	+23.95%
LKFT Lakefront Biotherapeutics American Depositary Shares	0.00%	-2.26%	-10.46%	-2.82%	-16.81%
OCUL Ocular Therapeutix	0.00%	-4.00%	-15.25%	-13.36%	-31.46%
PROK ProKidney	0.00%	+2.67%	-24.14%	-20.21%	-45.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	2.67	Moderate Buy	$105.00	32.51% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.11	Hold	$34.33	26.18% Upside
OCUL Ocular Therapeutix	2.71	Moderate Buy	$25.11	207.36% Upside
PROK ProKidney	2.50	Moderate Buy	$12.00	679.22% Upside

Current Analyst Ratings Breakdown

Latest PROK, LKFT, OCUL, and ANIP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	OCUL Ocular Therapeutix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	ANIP ANI Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$91.00
7/14/2026	OCUL Ocular Therapeutix	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/10/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Equal Weight	$30.00
7/10/2026	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$124.00
6/25/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $23.00
6/23/2026	ANIP ANI Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
6/18/2026	OCUL Ocular Therapeutix	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $30.00
6/18/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$21.00 ➝ $25.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$883.37M	2.04	$9.93 per share	7.98	$24.03 per share	3.30
LKFT Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.72	$0.73 per share	37.48	$47.57 per share	0.57
OCUL Ocular Therapeutix	$51.95M	34.44	N/A	N/A	$3.07 per share	2.66
PROK ProKidney	$890K	522.67	N/A	N/A	($3.36) per share	-0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$78.34M	$3.95	20.06	9.16	N/A	9.98%	27.51%	10.02%	8/7/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	8/10/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.46	N/A	N/A	N/A	-558.24%	-64.28%	-48.15%	8/4/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.53	N/A	N/A	N/A	-8,131.50%	N/A	-21.39%	8/11/2026 (Estimated)

Latest PROK, LKFT, OCUL, and ANIP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	PROK ProKidney	-$0.13	N/A	N/A	N/A	$0.19 million	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	N/A	N/A	N/A	$7.29 million	N/A
8/7/2026	Q2 2026	ANIP ANI Pharmaceuticals	$2.04	N/A	N/A	N/A	$260.13 million	N/A
8/4/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	N/A	N/A	N/A	$13.20 million	N/A
5/15/2026	Q1 2026	PROK ProKidney	-$0.13	-$0.14	-$0.01	-$0.14	$0.10 million	$0.23 million
5/8/2026	Q1 2026	ANIP ANI Pharmaceuticals	$1.28	$2.05	+$0.77	$1.28	$207.63 million	$237.46 million
5/6/2026	Q1 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$1.27	$0.25	+$1.52	$0.25	$11.26 million	$8.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.06	3.12	2.52
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	30.48	30.30
OCUL Ocular Therapeutix	0.12	14.81	14.73
PROK ProKidney	N/A	9.06	9.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
OCUL Ocular Therapeutix	59.21%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	8.10%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
OCUL Ocular Therapeutix	3.10%
PROK ProKidney	39.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	22.75 million	20.90 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
OCUL Ocular Therapeutix	230	218.96 million	212.17 million	Optionable
PROK ProKidney	3	302.06 million	181.75 million	Optionable

PROK, LKFT, OCUL, and ANIP Headlines

Recent News About These Companies

ProKidney Cell Therapy Thwarts Onerous Dialysis

July 30, 2026 | bloomberg.com

ProKidney (NASDAQ:PROK) Trading Down 0.7% - What's Next?

July 24, 2026 | americanbankingnews.com

ProKidney (NASDAQ:PROK) Trading Down 0.7% - Time to Sell?

July 24, 2026 | marketbeat.com

ProKidney Corp. (PROK) Latest Stock News & Headlines - Yahoo Finance

July 14, 2026 | finance.yahoo.com

ProKidney Corp (NASDAQ: PROK) - Share Price and Research

July 13, 2026 | intelligentinvestor.com.auI

What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite?

July 9, 2026 | kalkinemedia.comK

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path

June 17, 2026 | insidermonkey.com

ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout

June 2, 2026 | bizjournals.com

ProKidney Appoints Kenneth Locke as Chief Technical Officer

June 2, 2026 | globenewswire.com

ProKidney shareholders reaffirm board and auditor at 2026 meeting

May 29, 2026 | tipranks.com

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

May 15, 2026 | zacks.com

ProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial Results

May 15, 2026 | quiverquant.comQ

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

May 15, 2026 | globenewswire.com

ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel

May 2, 2026 | finance.yahoo.com

ProKidney Corp. Class A

April 14, 2026 | edition.cnn.com

April 2026 Penny Stock Highlights

April 3, 2026 | finance.yahoo.com

What Makes ProKidney Corp. (PROK) So Attractive

March 31, 2026 | insidermonkey.com

What makes ProKidney Corp. (PROK) so attractive

March 31, 2026 | msn.com

5 Best Penny Stocks That Could Triple Your Money

March 30, 2026 | insidermonkey.com

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

March 25, 2026 | globenewswire.com

ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of â€œModerate Buyâ€ by Brokerages

March 22, 2026 | defenseworld.netD

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, LKFT, OCUL, and ANIP Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$79.02 -0.22 (-0.28%)

As of 10:23 AM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$26.59 -0.62 (-2.28%)

As of 10:03 AM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Ocular Therapeutix NASDAQ:OCUL

$8.36 +0.20 (+2.39%)

As of 10:23 AM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

ProKidney NASDAQ:PROK

$1.56 +0.03 (+1.62%)

As of 10:23 AM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PROK, LKFT, OCUL, and ANIP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PROK, LKFT, OCUL, and ANIP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PROK, LKFT, OCUL, and ANIP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, LKFT, OCUL, and ANIP Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Ocular Therapeutix NASDAQ:OCUL

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PROK, LKFT, OCUL, and ANIP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PROK, LKFT, OCUL, and ANIP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PROK, LKFT, OCUL, and ANIP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, LKFT, OCUL, and ANIP Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Ocular Therapeutix NASDAQ:OCUL

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools